FDA Grants Expedited Approval to First-of-Its-Kind Pancreatic Cancer Pill Daraxonrasib

The US Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, a first-of-its-kind pill designed to block a mutated protein that drives tumor growth in more than 90% of pancreatic cancer cases. The drug targets the KRAS G12D mutation, a subtype of the KRAS gene that has eluded drug developers for decades.

Pancreatic cancer is among the most lethal malignancies, with a five-year survival rate of just 12%, according to the American Cancer Society. The disease is often diagnosed at advanced stages, leaving few treatment options. Current standard therapies include chemotherapy and surgery, but outcomes remain poor.

Daraxonrasib works by binding to and inhibiting the mutant KRAS protein, effectively shutting down the signaling pathway that allows cancer cells to proliferate. This approach, known as targeted therapy, has been successful in other cancers, such as lung cancer, but was long considered impossible for pancreatic cancer due to the unique structure of the KRAS protein.

The FDA's expedited approval was based on results from a Phase 2 clinical trial that showed daraxonrasib significantly improved progression-free survival and overall response rates in patients with advanced pancreatic cancer who had received prior treatment. The most common side effects included nausea, fatigue, and elevated liver enzymes, which were generally manageable.

While the approval represents a major step forward, experts caution that the drug is not a cure and that patients will still require careful monitoring. Further trials are planned to evaluate daraxonrasib in combination with other therapies and as an earlier treatment option.

Why This Matters

Pancreatic cancer is one of the deadliest cancers, with few effective treatments; daraxonrasib offers a new targeted option for patients who have exhausted standard therapies.
The approval validates a long-sought approach to blocking mutant KRAS, a protein previously considered "undruggable," paving the way for similar drugs in other cancers.
Expedited FDA approval means the drug will reach patients faster, but ongoing monitoring is needed to assess long-term efficacy and safety in real-world use.

Background

For decades, pancreatic cancer has been notoriously difficult to treat due to its late diagnosis and resistance to chemotherapy. The KRAS gene mutation is present in the vast majority of cases, but efforts to develop drugs that directly target it failed repeatedly because the protein lacks convenient binding sites for inhibitors. Recent breakthroughs in understanding KRAS structure, particularly the G12C mutation in lung cancer, spurred renewed interest. Daraxonrasib is the first to target the G12D mutation, which is more common in pancreatic cancer. The FDA's expedited approval process, designed for drugs that address unmet medical needs, allowed daraxonrasib to reach patients after promising Phase 2 data, short of the typical Phase 3 requirements.

Key Perspectives

Patients and advocacy groups: Welcomed the approval as a long-overdue advance, giving hope to the roughly 60,000 Americans diagnosed with pancreatic cancer each year. They urge access and affordability. Oncologists: Caution that while the drug is promising, it is not a cure, and many patients will eventually develop resistance. Combination therapies may be necessary. Critics: Some skeptics point to the lack of Phase 3 data and question whether expedited approvals could leave patients vulnerable to unforeseen side effects or marginal benefit. They call for rigorous post-marketing surveillance.

What to Watch

Results from ongoing Phase 3 trials to confirm the drug's survival benefit.
Insurance coverage and pricing decisions, which will determine patient access.
Developments in combination therapies, including daraxonrasib with immunotherapy or chemotherapy.

ZOTPAPER